This enduring dialogue aims to inform primary care clinicians, endocrinologists, and cardiologists about the most recent KDIGO guidelines for the management of chronic kidney disease (CKD) and evidence regarding the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) therapies for patients with CKD and type 2 diabetes (T2D). As a result of this educational activity, learners should be better able to: 1. Identify patients with type 2 diabetes (T2D) who are at high risk for chronic kidney disease (CKD) progression and cardiovascular events 2. Outline the clinical implications of updated CKD guidelines regarding the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) therapy in patients with T2D and CKD 3. Describe the latest evidence on the use of MRA therapies in individuals with T2D and CKD. Two featured faculty members (a nephrologist and cardiologist) are recognized as experts in managing CKF and T2D. Learners will be immersed in this educational dialogue through five approximately 3 minute, faculty-led audiovisual sessions. Learners will also have the opportunity to view a list of all sessions to allow easy access to those of greatest interest.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/YTP
- Start Date: 2024-11-15 06:00:00
- End Date: 2024-11-15 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Bayer (Any division) - Amount: 165392.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all